Hospital
Clhg-Acadian, LLC
Clhg-Acadian, LLC was paid $7.75M by Medicaid between Aug 2020 and Dec 2024, across 139 billing codes. Its largest line is 99284, emergency room visit (serious) — 36% of everything it billed.
33Billing provider infoCLHG-ACADIAN, LLC
EUNICE, LA 70535
EUNICE, LA 70535
33aNPI1396394961assigned 09/06/2019
33bProvider typeGeneral Acute Care Hospital
28Total paid$7.75M
24GClaims180,691
24DCodes billed139
24AFirst – last monthAug 2020 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Louisiana
Rank by total paid#40 of 96
Median peer was paid$5.17M
This provider vs. median1.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 12,592 | $609K | |
| 2021 | 40,748 | $2.64M | |
| 2022 | 48,275 | $2.42M | |
| 2023 | 51,199 | $1.30M | |
| 2024incomplete | 27,877 | $779K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 36% | 13,009 | 11,487 | $2.76M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 25% | 11,632 | 10,469 | $1.92M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 10% | 2,603 | 2,244 | $783K |
| G0378 | Hospital observation service, per hour | 4.0% | 815 | 663 | $308K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 3.3% | 5,101 | 4,536 | $254K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 2.4% | 790 | 703 | $185K |
| 58662 | 2.2% | 436 | 310 | $174K | |
| 71045 | Radiologic examination, chest; single view | 1.7% | 3,293 | 2,910 | $135K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.3% | 2,803 | 2,485 | $103K |
| 80053 | Comprehensive metabolic panel | 1.1% | 14,863 | 12,618 | $82K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,641 | 1,339 | $73K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,225 | 1,123 | $67K |
127 more codes
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 205 | $58K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 15,219 | $58K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 199 | $55K |
| 87276 | <1% | 4,114 | $52K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 4,453 | $48K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,633 | $48K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 7,120 | $46K |
| 58558 | <1% | 95 | $43K | |
| 87275 | <1% | 3,955 | $38K | |
| 58563 | <1% | 65 | $29K | |
| 80050 | General health panel | <1% | 665 | $27K |
| 36415 | Collection of venous blood by venipuncture | <1% | 16,475 | $25K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,784 | $24K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 237 | $24K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 106 | $24K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 598 | $24K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 196 | $18K |
| 81025 | <1% | 2,288 | $15K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 87 | $15K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 32 | $14K |
| 74019 | <1% | 266 | $13K | |
| 93017 | <1% | 198 | $13K | |
| G0379 | Direct admission of patient for hospital observation care | <1% | 304 | $12K |
| 81001 | <1% | 6,227 | $11K | |
| 84702 | <1% | 3,147 | $9K | |
| 59025 | Fetal non-stress test | <1% | 102 | $8K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,588 | $8K |
| 80061 | Lipid panel | <1% | 666 | $7K |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 199 | $7K |
| 85730 | <1% | 2,903 | $7K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 139 | $6K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 12 | $6K |
| 87081 | <1% | 1,082 | $6K | |
| 84439 | <1% | 780 | $6K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 81 | $6K |
| 85610 | <1% | 2,967 | $5K | |
| 93970 | <1% | 69 | $5K | |
| 0598T | <1% | 140 | $5K | |
| 83735 | <1% | 1,055 | $4K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 624 | $4K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 353 | $4K |
| 84484 | <1% | 432 | $3K | |
| 87280 | <1% | 259 | $3K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 138 | $3K |
| 87040 | <1% | 270 | $3K | |
| 81003 | <1% | 2,475 | $3K | |
| 83655 | <1% | 248 | $3K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 182 | $3K |
| 83690 | <1% | 585 | $3K | |
| 86850 | <1% | 3,001 | $3K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 233 | $2K |
| 74018 | <1% | 50 | $2K | |
| 86803 | <1% | 146 | $2K | |
| 73562 | <1% | 30 | $2K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 764 | $2K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,951 | $2K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 44 | $2K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,460 | $2K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 98 | $1K |
| 82550 | <1% | 332 | $1K | |
| 82553 | <1% | 181 | $1K | |
| 86901 | <1% | 3,059 | $1K | |
| 86592 | <1% | 1,093 | $1K | |
| 86900 | <1% | 3,053 | $1K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 170 | $1K |
| 82105 | <1% | 70 | $1K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 144 | $1K |
| 83880 | <1% | 41 | $902.98 | |
| 86706 | <1% | 76 | $801.47 | |
| 86762 | <1% | 60 | $800.44 | |
| 86787 | <1% | 63 | $793.73 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 89 | $763.82 |
| 84153 | <1% | 46 | $753.99 | |
| 84146 | <1% | 42 | $736.44 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,124 | $684.70 |
| 87340 | <1% | 61 | $584.93 | |
| 84144 | <1% | 33 | $584.08 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 65 | $534.05 |
| 82670 | <1% | 21 | $530.86 | |
| 84100 | <1% | 1,034 | $512.91 | |
| 36416 | <1% | 273 | $504.86 | |
| 84403 | <1% | 21 | $490.39 | |
| 84402 | <1% | 21 | $483.93 | |
| 30140 | <1% | 105 | $481.27 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 1,773 | $448.76 |
| 82627 | <1% | 20 | $400.14 | |
| J2704 | Injection, propofol, 10 mg | <1% | 4,353 | $395.10 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 27 | $386.40 |
| 87430 | <1% | 26 | $384.10 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 23 | $372.41 |
| 83001 | <1% | 22 | $371.60 | |
| 83002 | <1% | 22 | $370.40 | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 13 | $356.96 |
| 86703 | <1% | 28 | $347.49 | |
| 82157 | <1% | 12 | $322.08 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 12 | $296.00 |
| 84481 | <1% | 28 | $228.38 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 152 | $226.50 |
| 85027 | <1% | 43 | $194.10 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 17 | $191.35 |
| 82785 | <1% | 41 | $181.06 | |
| 83020 | <1% | 13 | $167.31 | |
| C1769 | Guide wire | <1% | 14 | $143.68 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 80 | $142.93 |
| 82950 | <1% | 28 | $133.00 | |
| 84270 | <1% | 21 | $118.56 | |
| 83605 | <1% | 14 | $115.70 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 2,193 | $111.94 |
| 82150 | <1% | 19 | $103.68 | |
| 85018 | <1% | 40 | $90.06 | |
| 85007 | <1% | 43 | $85.40 | |
| 85014 | <1% | 28 | $61.62 | |
| A6213 | Foam dressing, wound cover, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., with any size adhesive border, each dressing | <1% | 35 | $49.28 |
| A6199 | Alginate or other fiber gelling dressing, wound filler, sterile, per 6 inches | <1% | 28 | $45.88 |
| A6216 | Gauze, non-impregnated, non-sterile, pad size 16 sq. in. or less, without adhesive border, each dressing | <1% | 240 | $45.17 |
| A6443 | Conforming bandage, non-elastic, knitted/woven, non-sterile, width greater than or equal to three inches and less than five inches, per yard | <1% | 59 | $29.94 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 270 | $23.08 |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | <1% | 237 | $14.63 |
| 82962 | <1% | 18 | $3.26 | |
| A6253 | Specialty absorptive dressing, wound cover, sterile, pad size more than 48 sq. in., without adhesive border, each dressing | <1% | 15 | $2.40 |
| 05983 | 0% | 498 | $0.00 | |
| L8699 | Prosthetic implant, not otherwise specified | 0% | 162 | $0.00 |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 0% | 1,454 | $0.00 |
| A9270 | Non-covered item or service | 0% | 23 | $0.00 |
| A4649 | Surgical supply; miscellaneous | 0% | 159 | $0.00 |
| C1780 | Lens, intraocular (new technology) | 0% | 37 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 69 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialFRANK, KEVIN (CEO-ADMINISTRATOR)
| Provider | Location | Paid |
|---|---|---|
| Clhg-Acadian LLC | Eunice, LA | $5.50M |
| Clhg-Acadian LLC | Eunice, LA | $845K |
| Clhg-Acadian LLC | Church Point, LA | $617K |
| Clhg-Acadian LLC | Basile, LA | $474K |
| Clhg-Acadian LLC | Eunice, LA | $152K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.